DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 307,100 shares, an increase of 6.3% from the July 15th total of 288,800 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 94,100 shares, the days-to-cover ratio is presently 3.3 days.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on DBVT shares. StockNews.com began coverage on shares of DBV Technologies in a research note on Sunday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st. Finally, JMP Securities lifted their target price on DBV Technologies from $4.00 to $5.00 and gave the company a “market outperform” rating in a report on Wednesday, July 31st.
View Our Latest Research Report on DBVT
Institutional Investors Weigh In On DBV Technologies
DBV Technologies Price Performance
Shares of DBVT traded down $0.01 during midday trading on Friday, reaching $0.93. The stock had a trading volume of 5,736 shares, compared to its average volume of 51,975. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $3.70. The company has a market cap of $89.98 million, a price-to-earnings ratio of -1.11 and a beta of 0.68. The company’s fifty day simple moving average is $0.91 and its two-hundred day simple moving average is $1.26.
DBV Technologies (NASDAQ:DBVT – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the prior year, the company earned ($0.26) earnings per share. On average, sell-side analysts forecast that DBV Technologies will post -1.22 earnings per share for the current year.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Read More
- Five stocks we like better than DBV Technologies
- 3 Healthcare Dividend Stocks to Buy
- This Small Cap Wealth Management Stock Could Provide Big Returns
- CD Calculator: Certificate of Deposit Calculator
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.